Psilera Closes $8.8M Seed to Push Neuroplastogen Toward Clinic

May 31, 2026

Fundraise Insider tracks newly funded startups each week and delivers verified C-suite contacts straight to your inbox, so you reach the right people while the funding is still fresh. See pricing.

Psilera, a Tampa-based biopharmaceutical company developing next-generation neuroplastogens and psychedelic therapies, has closed an oversubscribed $8.8 million Seed extension round. A syndicate of institutional and strategic investors led the financing, which closed on May 28, 2026.

The company plans to use the funds to advance its lead clinical asset, PSIL-006, toward first-in-human trials in 2027.

PSIL-006 is a first-in-class neuroplastogen designed to capture the therapeutic benefits of traditional psychedelic compounds while reducing hallucinogenic effects and cardiovascular risks.

Psilera was co-founded in 2019 by Chris Witowski, who serves as chief executive officer, and Jackie von Salm, who serves as chief science officer.

You may also like

35 Sales Email Tips to Crush Your Sales Game

In today’s digital age, email remains one of the most effective tools for reaching out to potential customers and driving sales. However, crafting a successful sales email can be tricky, as you need […]

Recently Funded Startups Are A Great Sales Target. Here’s Why.

The startup industry has been growing at an unprecedented rate in recent years, with billions of dollars being poured into the sector every year. This growth has created an opportunity for businesses to […]

How to Identify Your B2B Target Audience: A Comprehensive Guide

For any business to succeed, it is essential to target the right audience. In B2B marketing, identifying your target audience is even more important, as it helps you focus your efforts and resources […]